AZ084

$166$2,250

Products Details

Product Description

– AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma[1]. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer[1][2].

Web ID

– HY-119217

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C26H34N4O2

References

– [1]Wang M, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer Immunol Immunother. 2022 Apr 15. |[2]Connolly S, et al. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem Pharmacol. 2012 Mar 15;83(6):778-87.

CAS Number

– 929300-19-6

Molecular Weight

– 434.57

Compound Purity

– 99.69

SMILES

– O=C(C1=NC=C(N)C=C1)N2CCC3(CCN(CC4=C5CC(C)(C)OC5=CC=C4)CC3)CC2

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Endocrinology

Solubility

– DMSO : 250 mg/mL (ultrasonic)

Target

– CCR

Isoform

– CCR8

Pathway

– GPCR/G Protein;Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=